Lucassmedegaard3624

BACKGROUND The liver is a frequent site of surgical resection for both benign and malignant lesions. Advanced knowledge of the hepatic arterial system and its variants is crucial to avoid incidental injuries during a resection procedure. Many variants have been previously described in the literature, yet extremely rare cases continue to be encountered in clinical practice. Documentation of these variants can thus allow for proper preoperative procedural planning when considering interventions involving the liver. Our aim is to present one such unique and extremely rare anomaly. CASE REPORT During routine cadaveric dissection of a 78-year-old man who had died of acute myeloid leukemia, a rare anatomic variant of the hepatic vasculature was revealed a replaced right hepatic artery (rRHA) coming directly from the celiac trunk, a middle hepatic artery (MHA) continuing from the common hepatic artery (CHA), and a replaced left hepatic artery (rLHA) branching from the left gastric artery (LGA). To the best of our knowledge, this anomaly has only been described once before in the literature. CONCLUSIONS We report a rare anatomical variant of the hepatic vasculature. The significance of this variant must be considered during preoperative planning and the intra-arterial infusion of targeted drugs. This case further emphasizes the importance of proper medical imaging and documentation to ensure the best course of treatment for each patient. Given that this variant has only so far been identified in 2 post-mortem subjects, further work should include attempts at characterizing its physiologic effects in a living patient.BACKGROUND This study aimed to investigate the epidemiology of influenza viruses and viruses that caused influenza-like disease in children under 14 years of age in the 2018-2019 epidemic season in Poland, and to identify the public health lessons that can be learned. MATERIAL AND METHODS Nose and throat swabs were used to obtain samples. The samples were analyzed in the National Influenza Center, Department of Influenza Research at the National Institute of Public Health-National Institute of Hygiene as well as in 16 Voivodship Sanitary Epidemiological Stations across the country. Methods of RNA isolation depended on the laboratory where the isolation was performed. In all laboratories, quantitative polymerase chain reactions were used to determine the influenza virus type as well as the subtype. RESULTS The study group was confirmed to be infected with influenza A and B, with influenza A/H1N1/pdm09 as the dominant subtype. Among the age group of children up to 14 years of age, cases of infection with viruses that cause influenza-like disease were also reported. It was noticeable that the largest number of confirmed cases of infection was recorded in the group of the youngest children (0-4 years). AZD1480 In addition, several different variants of co-infection were registered. CONCLUSIONS This population study showed that in the 2018-2019 epidemic season in Poland children aged under 14 years were at risk of influenza virus infection and its complications. The presented data support increasing the percentage of children being vaccinated in Poland.

With the development and use of pesticide products increasing, information on the safe handling of pesticides becomes increasingly important. In this article, the denomination of lung toxicity on labelling is reviewed.

The results highlight that whereas hazards, warning statements and instructions for safe use are broadly defined, the different categories of products used as pesticides are associated with different types of clinical manifestations of toxicity. These clinical manifestations are however not directly warned for by means of information provided on the label more overarching terminology is used to describe hazards associated with acute toxicity, respiratory sensitization, specific lung toxicity after single or repeated exposure, as well as hazards from aspiration.

This misalignment between hazard labelling and experienced issues increases the difficulty for users of products and clinicians in dealing with adverse events. Together with ensuring that in risk assessment, an integrated approach is taken to study pesticide products, improving the labels will support the safe handling of pesticides.

This misalignment between hazard labelling and experienced issues increases the difficulty for users of products and clinicians in dealing with adverse events. Together with ensuring that in risk assessment, an integrated approach is taken to study pesticide products, improving the labels will support the safe handling of pesticides.

Anal cancer precursor lesions high-grade anal intraepithelial neoplasia (HGAIN) are highly prevalent among HIV+ men-who-have-sex-with-men (MSM). Treatment of HGAIN is frustrated by high recurrence rates. We investigated the efficacy of the quadrivalent human papillomavirus (qHPV) vaccine as post-treatment adjuvant in preventing HGAIN recurrence in HIV+MSM.

Randomised, double-blind, placebo-controlled, multicentre trial.

Three HIV outpatient clinics in Amsterdam, the Netherlands.

HIV+MSM with CD4 count >350 cells/μl, biopsy-proven intra-anal HGAIN successfully treated in the past year, and lesions still in remission at enrolment, as assessed by high-resolution anoscopy (HRA).

Participants were randomised to three doses of qHPV (Gardasil-4®, MSD) or placebo with vaccinations at 0, 2, and 6 months. HRA was repeated at 6, 12 and 18 months.

The primary outcome was cumulative, biopsy-proven HGAIN recurrence rate at 18 months, evaluated in an intention-to-treat (received all vaccinations) and per-protocol analysis (all vaccinations and complete follow-up).

We randomised 126 participants of which 64 (50.8%) received qHPV and 62 (49.2%) placebo. All participants received three vaccinations and in both groups for two participants follow-up was incomplete. We found no difference (p = 0·38) in cumulative HGAIN recurrence rates between the qHPV (44/64, 68.8%) and placebo group (38/62, 61.3%) in the intention-to-treat analysis (absolute risk reduction -7.5 (95%CI -24.1-9.2)). This was similar in the per-protocol analysis.

Despite adequate serological responses to qHPV vaccination, short-term recurrence of HGAIN was not prevented. These findings do not support qHPV vaccination as a treatment adjuvant to prevent HGAIN recurrence in HIV+MSM.

Despite adequate serological responses to qHPV vaccination, short-term recurrence of HGAIN was not prevented. These findings do not support qHPV vaccination as a treatment adjuvant to prevent HGAIN recurrence in HIV+MSM.